GlassScriptPhysician profile
Elliot Rudnitzky
NPI 1215967534
$910.64
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.35 · 2020: $197 · 2021: $215 · 2022: $174 · 2023: $58.43 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $285.93 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $119.96 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $69.71 | 2021-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $67.29 | 2019-2021 | |
| Novo Nordisk INC | $60.42 | 2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $55.78 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $50.89 | 2021 | |
| Pfizer INC. | $42.29 | 2019-2022 | |
| Cvrx, INC. | $40.49 | 2023-2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $29.16 | 2020 | |
| Merck Sharp & Dohme LLC | $27.45 | 2020-2021 | |
| Amarin Pharma, INC. | $23.50 | 2020-2021 | |
| Boston Scientific Corporation | $20.97 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $16.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Rudnitzky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.